1. Market Research
  2. > Biotechnology Market Trends
  3. > Biotechnology Analysis & Statistics in Japan, September 2019

Biotechnology Analysis & Statistics in Japan, September 2019

Customer Support

Talk to Veronica

+1 718 514 2762

Publishers

  • All
    • Pharma Intelligence

All regions

data types

1-18 of 18 reports

Psoriasis Pricing, Reimbursement, and Access

Psoriasis Pricing, Reimbursement, and Access

  • $ 2995
  • Industry report
  • March 2019

Launch of multiple IL inhibitors with impressive efficacy has significantly reduced unmet need in the disease, and also provided payers with leverage in price negotiations as they seek to control growing ...

  • Industries : Medical Biotechnology
  • Countries : United States, European Union, Japan
Gazyva

Gazyva

  • $ 10000
  • Industry report
  • January 2019

Drug OverviewGazyva (obinutuzumab; Roche/Biogen/Chugai/Nippon Shinyaku) is a third-generation, type II glycoengineered, humanized anti-CD20 monoclonal antibody (MAb) that recognizes the type II epitope ...

  • Industries : Medical Biotechnology, Therapy, Biopharmaceutical, Biopharmaceutical
  • Countries : United States, European Union, Japan
Arzerra

Arzerra

  • $ 10000
  • Industry report
  • January 2019

Drug OverviewArzerra (ofatumumab; Genmab/Novartis) is a fully human immunoglobulin G1 and high-affinity antibody that targets a novel epitope on cluster of differentiation 20 (CD20) on the B-cell membrane. ...

  • Industries : Medical Biotechnology, Therapy, Biopharmaceutical, Biopharmaceutical
  • Countries : United States, Europe, Japan, European Union
Yescarta

Yescarta

  • $ 10000
  • Industry report
  • January 2019

Drug OverviewYescarta (axicabtagene ciloleucel; Gilead) became the first chimeric antigen receptor T-cell (CAR-T) therapy to launch for the treatment of diffuse large B-cell lymphoma (DLBCL) when it gained ...

  • Industries : Medical Biotechnology, Cancer, Pathology, Biopharmaceutical, Biopharmaceutical
  • Countries : United States, Japan, European Union
Zevalin

Zevalin

  • $ 10000
  • Industry report
  • January 2019

Drug OverviewZevalin (ibritumomab tiuxetan; Acrotech Biopharma/Mundipharma) is an intravenous radioactive agent consisting of the murine monoclonal antibody (MAb) ibritumomab, which is covalently linked ...

  • Industries : Medical Biotechnology, Therapy, Biopharmaceutical, Biopharmaceutical
  • Countries : United States, Europe, Japan
lisocabtagene maraleucel

lisocabtagene maraleucel

  • $ 10000
  • Industry report
  • January 2019

Drug OverviewLisocabtagene maraleucel (also known as JCAR017; Celgene) will be the third autologous chimeric antigen receptor T-cell (CAR-T) therapy to reach the diffuse large B-cell lymphoma (DLBCL) market ...

  • Industries : Cancer, Medical Biotechnology, Pathology, Biopharmaceutical, Biopharmaceutical
  • Countries : United States, Japan, European Union
Blincyto

Blincyto

  • $ 10000
  • Industry report
  • October 2018

Drug OverviewBlincyto (blinatumomab; Amgen/AstraZeneca/Astellas), produced in Chinese hamster ovary cells, is a bispecific T-cell engager that directs T-cells to target CD19-positive benign and malignant ...

  • Industries : Medical Biotechnology, Biopharmaceutical, Biopharmaceutical, Cancer
  • Countries : United States, Japan, European Union
polatuzumab vedotin

polatuzumab vedotin

  • $ 10000
  • Industry report
  • October 2018

Drug OverviewPolatuzumab vedotin (Roche) is an antibody-drug conjugate (ADC) that combines a humanized immunoglobulin (Ig)-G1 monoclonal antibody (MAb) targeting human B-cell surface antigen cluster of ...

  • Industries : Therapy, Medical Biotechnology, Oncology, Biopharmaceutical, Biopharmaceutical
  • Countries : United States, Japan, European Union
Portrazza

Portrazza

  • $ 10000
  • Industry report
  • August 2018

Drug OverviewPortrazza (necitumumab; Eli Lilly) is a recombinant IgG1 monoclonal antibody (MAb) that blocks the binding of epidermal growth factor receptor (EGFR) to its ligands. This binding prevents ...

  • Industries : Therapy, Medical Biotechnology, Oncology, Biopharmaceutical, Biopharmaceutical
  • Countries : United States, Japan, European Union
Pomalyst

Pomalyst

  • $ 10000
  • Industry report
  • August 2018

Drug OverviewPomalyst (pomalidomide; Celgene) is an oral class I thalidomide analog, immunomodulatory drug with antineoplastic activity. In vitro studies have shown that the drug acts through multiple ...

  • Industries : Medical Biotechnology, Biopharmaceutical, Biopharmaceutical
  • Countries : United States, Japan, European Union
Isatuximab

Isatuximab

  • $ 10000
  • Industry report
  • August 2018

Drug OverviewIsatuximab (Sanofi/ImmunoGen) is a humanized monoclonal antibody which targets cancer cells expressing the transmembrane glycoprotein CD38, which is highly expressed on malignant multiple ...

  • Industries : Medical Biotechnology, Therapy, Biopharmaceutical, Biopharmaceutical
  • Countries : United States, Japan, European Union
Thalomid

Thalomid

  • $ 10000
  • Industry report
  • August 2018

Drug OverviewThalomid (Celgene) contains thalidomide, a glutamic acid derivative that possesses immunomodulatory, anti-inflammatory, and anti-angiogenic properties. The drug’s mechanism of action is ...

  • Industries : Medical Biotechnology, Biopharmaceutical, Biopharmaceutical
  • Countries : United States, Japan, European Union
Empliciti

Empliciti

  • $ 10000
  • Industry report
  • August 2018

Drug OverviewEmpliciti (elotuzumab; Bristol-Myers Squibb/AbbVie) is a monoclonal antibody that targets the signaling lymphocytic activation molecule family, member 7 (SLAMF7), also called CS1. This cell-surface ...

  • Industries : Medical Biotechnology, Therapy, Biopharmaceutical, Biopharmaceutical
  • Countries : United States, Japan, European Union
Alofisel

Alofisel

  • $ 10000
  • Industry report
  • August 2018

DRUG OVERVIEWAlofisel (darvadstrocel; TiGenix/Takeda) is a suspension of allogeneic expanded adipose-derived stem cells via intralesional injection. The therapy is being developed in Crohn’s disease ...

  • Industries : Medical Biotechnology, Biopharmaceutical, Biopharmaceutical, Therapy
  • Countries : United States, Japan, European Union
Risankizumab

Risankizumab

  • $ 10000
  • Industry report
  • August 2018

Drug OverviewRisankizumab (AbbVie/Boehringer Ingelheim) is a humanized anti-interleukin (IL)-23 subunit p19 monoclonal antibody that binds and neutralizes the p19 subunit of IL-23. It is being developed ...

  • Industries : Medical Biotechnology, Pathology, Biopharmaceutical, Biopharmaceutical
  • Countries : Japan, European Union
Entyvio

Entyvio

  • $ 10000
  • Industry report
  • August 2018

Drug OverviewEntyvio (vedolizumab; Takeda) is a monoclonal antibody approved for the treatment of Crohn’s disease. It inhibits the alpha-4-beta-7 integrin receptor, preventing the migration of T cells ...

  • Industries : Medical Biotechnology, Pathology, Therapy, Biopharmaceutical, Biopharmaceutical
  • Countries : United States, Japan, European Union
Inclisiran

Inclisiran

  • $ 10000
  • Industry report
  • June 2018

OverviewInclisiran (The Medicines Company/Alnylam Pharmaceuticals) is a systemically delivered siRNA therapeutic targeting mRNA for PCSK. Inclisiran targets both intracellular and extracellular PCSK9, ...

  • Industries : Medical Biotechnology, Therapy, Biopharmaceutical, Biopharmaceutical, Oncology
  • Countries : United States, Japan, European Union
Enbrel

Enbrel

  • $ 10000
  • Industry report
  • May 2018

Drug OverviewEnbrel (etanercept; Amgen/Pfizer/Takeda) is a dimeric fusion protein consisting of the extracellular ligand binding portion of tumor necrosis factor (TNF) receptor linked to the Fc portion ...

  • Industries : Medical Biotechnology, Pathology, Biopharmaceutical, Biopharmaceutical
  • Countries : United States, Japan, European Union



Reportlinker.com © Copyright 2019. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on